Reuters logo
BRIEF-Sumitomo Dainippon Pharma looks to expand applications of drug candidate Dasotraline - Nikkei
March 24, 2017 / 9:41 PM / 6 months ago

BRIEF-Sumitomo Dainippon Pharma looks to expand applications of drug candidate Dasotraline - Nikkei

March 24 (Reuters) - Nikkei

* Sumitomo Dainippon Pharma Co Ltd looks to expand the applications of its drug candidate dasotraline - Nikkei

* Sumitomo Dainippon Pharma’s candidate dasotraline has been tested in trials as ADHD treatment,now being studied as treatment for eating disorder -Nikkei

* Sumitomo Dainippon Pharma Co Ltd aims to begin sales of dasotraline in fiscal 2018 - Nikkei

* Sumitomo dainippon pharma co expects to file NDA with U.S. FDA in fiscal 2017 for ADHD indication and following year for binge eating disorder - Nikkei Source text : [s.nikkei.com/2n0i6kY] Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below